Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China".
作者信息
Guan Haijing, Sheng Yanan, Guo Wanjie, Han Sheng, Shi Luwen
机构信息
School of Pharmaceutical Sciences, Peking University, Beijing, China.
China Center for Health Economic Research, Peking University, Beijing, China.
出版信息
Adv Ther. 2020 Feb;37(2):971-972. doi: 10.1007/s12325-019-01202-2. Epub 2020 Jan 4.
Abstract
摘要
相似文献
1
Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China".
Adv Ther. 2020 Feb;37(2):971-972. doi: 10.1007/s12325-019-01202-2. Epub 2020 Jan 4.
2
Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China.
Adv Ther. 2020 Feb;37(2):968-970. doi: 10.1007/s12325-019-01204-0. Epub 2020 Jan 4.
3
Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.
Adv Ther. 2019 May;36(5):1114-1125. doi: 10.1007/s12325-019-00908-7. Epub 2019 Mar 21.
4
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.
5
The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
J Med Econ. 2017 Jul;20(7):671-677. doi: 10.1080/13696998.2017.1302453. Epub 2017 Mar 23.
6
Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
Anticancer Drugs. 2016 Jul;27(6):573-5. doi: 10.1097/CAD.0000000000000356.
7
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
Int J Oncol. 2015 Mar;46(3):1025-30. doi: 10.3892/ijo.2014.2797. Epub 2014 Dec 15.
8
Alectinib for treatment of ALK-positive non-small-cell lung cancer.
Future Oncol. 2017 Feb;13(4):321-335. doi: 10.2217/fon-2016-0386. Epub 2016 Oct 26.
9
Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
Cancer Chemother Pharmacol. 2016 Mar;77(3):623-8. doi: 10.1007/s00280-016-2977-y. Epub 2016 Feb 5.
10
Alectinib for the treatment of ALK-positive stage IV non-small cell lung cancer.
Drugs Today (Barc). 2015 Mar;51(3):161-70. doi: 10.1358/dot.2015.51.3.2294597.
本文引用的文献
1
Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer.
Pharmacoeconomics. 2018 Apr;36(4):495-504. doi: 10.1007/s40273-018-0625-6.
2
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Lancet. 2017 Jul 1;390(10089):29-39. doi: 10.1016/S0140-6736(17)30565-2. Epub 2017 May 10.
3
Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide.
Med Decis Making. 2013 Aug;33(6):743-54. doi: 10.1177/0272989X12472398. Epub 2013 Jan 22.
Zotero 插件